STUB1 and myelodysplastic syndrome: CHIP is by definition incidentally identified, but carries risks for subsequent development of myeloid neoplasms (e.g. MDS, AML), as well as nonneoplastic morbidities (e.g. cardiovascular events); however, the magnitude of risk is dependent on multiple factors, such as the specific gene mutation type, VAF, or prior exposure to DNA‐damaging agents (e.g. solid tumour treatment).